JP2013513564A5 - - Google Patents

Download PDF

Info

Publication number
JP2013513564A5
JP2013513564A5 JP2012542487A JP2012542487A JP2013513564A5 JP 2013513564 A5 JP2013513564 A5 JP 2013513564A5 JP 2012542487 A JP2012542487 A JP 2012542487A JP 2012542487 A JP2012542487 A JP 2012542487A JP 2013513564 A5 JP2013513564 A5 JP 2013513564A5
Authority
JP
Japan
Prior art keywords
oxy
methyl
pyridinyl
phenyl
imidazolidinedione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012542487A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013513564A (ja
JP5788404B2 (ja
Filing date
Publication date
Priority claimed from GB0921760A external-priority patent/GB0921760D0/en
Priority claimed from GBGB1012924.5A external-priority patent/GB201012924D0/en
Application filed filed Critical
Priority claimed from PCT/EP2010/068946 external-priority patent/WO2011069951A1/en
Publication of JP2013513564A publication Critical patent/JP2013513564A/ja
Publication of JP2013513564A5 publication Critical patent/JP2013513564A5/ja
Application granted granted Critical
Publication of JP5788404B2 publication Critical patent/JP5788404B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012542487A 2009-12-11 2010-12-06 イミダゾリジンジオン誘導体 Expired - Fee Related JP5788404B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0921760A GB0921760D0 (en) 2009-12-11 2009-12-11 Novel compounds
GB0921760.5 2009-12-11
GB1012924.5 2010-07-30
GBGB1012924.5A GB201012924D0 (en) 2010-07-30 2010-07-30 Novel compounds
PCT/EP2010/068946 WO2011069951A1 (en) 2009-12-11 2010-12-06 Imidazolidinedione derivatives

Publications (3)

Publication Number Publication Date
JP2013513564A JP2013513564A (ja) 2013-04-22
JP2013513564A5 true JP2013513564A5 (https=) 2014-02-06
JP5788404B2 JP5788404B2 (ja) 2015-09-30

Family

ID=43446689

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012542487A Expired - Fee Related JP5788404B2 (ja) 2009-12-11 2010-12-06 イミダゾリジンジオン誘導体

Country Status (16)

Country Link
US (7) US8722695B2 (https=)
EP (1) EP2509961B1 (https=)
JP (1) JP5788404B2 (https=)
KR (1) KR101735675B1 (https=)
CN (1) CN102753533B (https=)
AU (1) AU2010330048B9 (https=)
BR (1) BR112012015868A2 (https=)
CA (1) CA2781685C (https=)
DK (1) DK2509961T3 (https=)
EA (1) EA019970B8 (https=)
ES (1) ES2575215T3 (https=)
IL (1) IL219628A (https=)
MX (1) MX2012006615A (https=)
PL (1) PL2509961T3 (https=)
WO (1) WO2011069951A1 (https=)
ZA (1) ZA201203233B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8519176B1 (en) * 2009-10-05 2013-08-27 Boehringer Ingelheim International Gmbh Process for preparation of substituted P-aminophenol
JP5788404B2 (ja) * 2009-12-11 2015-09-30 アウトイフオンイ トヘラペウトイクス リミテッド イミダゾリジンジオン誘導体
DK2624695T3 (en) 2010-10-08 2016-01-04 Nivalis Therapeutics Inc NOVEL SUBSTITUTED quinoline-RELATIONS AS S-NITROSOGLUTATHIONREDUKTASEINHIBITORER
EP2649066B1 (en) 2010-12-06 2015-10-21 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
US9193704B2 (en) * 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
AU2012349847B2 (en) * 2011-12-06 2017-02-16 Autifony Therapeutics Limited Hydantoin derivatives useful as Kv3 inhibitors
US9422252B2 (en) 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
EP2852588B8 (en) * 2012-05-22 2018-01-10 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
WO2013182851A1 (en) * 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
PL3040329T3 (pl) * 2013-08-29 2019-04-30 Kyoto Pharma Ind Związek aromatyczny i jego zastosowanie w leczeniu chorób związanych z metabolizmem kości
SG10201912805SA (en) * 2014-12-19 2020-02-27 Aragon Pharmaceuticals Inc Process for the preparation of a diarylthiohydantoin compound
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
CN105837453A (zh) * 2016-03-31 2016-08-10 常州大学 一种3,5-二氯-4’-硝基二苯醚的合成方法
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
CN108101811A (zh) 2016-11-25 2018-06-01 斯福瑞（南通）制药有限公司 生产n-叔丁氧羰基-2-氨基-3,3-二甲基丁酸的方法
WO2018109484A1 (en) 2016-12-16 2018-06-21 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
CN110785413B (zh) 2017-05-02 2024-08-02 Fmc公司 作为除草剂的嘧啶氧基苯并稠合化合物
WO2018220762A1 (ja) * 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
WO2019222816A1 (en) 2018-09-21 2019-11-28 Bionomics Limited Substituted-pyridinyl compounds and uses thereof
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
TWI827706B (zh) 2018-10-16 2024-01-01 英商奧堤凡尼治療股份有限公司 新穎化合物
JP6870064B2 (ja) * 2018-11-30 2021-05-12 大塚製薬株式会社 ピリミジン化合物の医薬用途
SG11202104374WA (en) * 2018-11-30 2021-05-28 Otsuka Pharma Co Ltd Heterocyclic compounds for the treatment of epilepsy
JP7551641B2 (ja) * 2019-03-25 2024-09-17 バイオノミクス リミテッド 置換ｎ－ヘテロアリール化合物及びその使用
JP7522203B2 (ja) 2020-02-06 2024-07-24 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３モジュレーター
EP3901152A1 (en) * 2020-04-23 2021-10-27 F. Hoffmann-La Roche AG Kv3 enhancers for the treatment of cognitive disorders
GB2594931A (en) * 2020-05-06 2021-11-17 Syngenta Crop Protection Ag Improvements in or relating to organic compounds
US20240327406A1 (en) 2021-08-10 2024-10-03 Autifony Therapeutics Limited Potassium channel modulators
CN114605331A (zh) * 2022-03-17 2022-06-10 上海健康医学院 一种尼鲁米特及其中间体的制备方法
WO2023186690A1 (de) * 2022-03-28 2023-10-05 Bayer Aktiengesellschaft Substituierte 2-aminoazine sowie deren salze und ihre verwendung als herbizide wirkstoffe
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1147725A (en) * 1966-03-30 1969-04-02 Mitsui Kagaku Kogyo Kabushiki Novel halodiphenylethers for use as herbicides
US4099007A (en) * 1969-04-02 1978-07-04 Hoechst Aktiengesellschaft N,n-substituted 2,4,5-triketoimidazolidines and a process for their preparation
DE2916647A1 (de) * 1979-04-25 1980-11-06 Basf Ag Parabansaeurederivate
DE3015090A1 (de) 1980-04-19 1981-10-22 Basf Ag, 6700 Ludwigshafen ]-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one, verfahren zu ihrer herstellung, diese enthaltende fungizide und verfahren zur bekaempfung von pilzen mit diesen verbindungen
DE3133405A1 (de) 1981-08-24 1983-03-10 Basf Ag, 6700 Ludwigshafen 1-(trihalogenmethyl-sulfenyl)-4-aryl-1,2,4-triazolidin-5-one und diese enthaltende fungizide
US4675403A (en) * 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity
JP2514945B2 (ja) 1987-02-05 1996-07-10 三井石油化学工業株式会社 芳香族アミン誘導体
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
DE3836175A1 (de) 1988-10-24 1990-05-03 Bayer Ag Fluor enthaltende phenole
WO1991004027A1 (en) 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
US5362878A (en) 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
FR2706456B1 (fr) * 1993-06-18 1996-06-28 Rhone Poulenc Agrochimie Dérivés optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
US6002016A (en) * 1991-12-20 1999-12-14 Rhone-Poulenc Agrochimie Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones
DK123493D0 (da) 1993-11-01 1993-11-01 Lundbeck & Co As H Compounds
WO1996036229A1 (en) 1995-05-17 1996-11-21 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
EP0825992A1 (en) 1995-05-17 1998-03-04 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
PL324291A1 (en) 1995-06-20 1998-05-11 Du Pont Anthropodicidal and fungicidal cyclic amides
BR9711816A (pt) 1996-08-01 1999-08-31 Du Pont Composto, composição fungicida, método para controlar doenças de plantas causadas pelos agentes patogênicos f·ngicos de plantas, composição artropodicida e método para controlar artrópodes.
WO1998023155A1 (en) 1996-11-26 1998-06-04 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal cyclic amides
KR20000057254A (ko) 1996-11-26 2000-09-15 메리 이. 보울러 메틸 치환된 살진균제 및 살절지동물제
AU6040398A (en) 1997-01-30 1998-08-25 E.I. Du Pont De Nemours And Company Fungicidal compositions
AU735137B2 (en) * 1997-02-21 2001-07-05 Bayer Intellectual Property Gmbh Arylsulphonamides and analogues and their use for the treatment and neurovegetative disorders
JP4171549B2 (ja) 1998-01-28 2008-10-22 大正製薬株式会社 含フッ素アミノ酸誘導体
AR015733A1 (es) * 1998-03-25 2001-05-16 Otsuka Pharma Co Ltd DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO.
JP2000072731A (ja) 1998-08-31 2000-03-07 Taisho Pharmaceut Co Ltd ４−置換−２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体及び製薬用組成物
JP4194715B2 (ja) 1998-08-31 2008-12-10 大正製薬株式会社 ６−フルオロビシクロ［３．１．０］ヘキサン誘導体
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
BR0012697A (pt) 1999-07-23 2002-04-09 Shionogi & Co Inibidores da diferenciação de th2
KR20030009416A (ko) 2000-04-04 2003-01-29 시오노기세이야쿠가부시키가이샤 고지용성 약물을 함유하는 유성 조성물
AU2001244610A1 (en) 2000-04-05 2001-10-23 Shionogi And Co., Ltd. Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof
FR2812633A1 (fr) 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
GB0026838D0 (en) 2000-11-02 2000-12-20 Glaxo Group Ltd Treatment method
AU2002354410A1 (en) 2001-12-05 2003-06-17 Japan Tobacco Inc. Triazole compound and medicinal use thereof
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
AU2003210916B9 (en) 2002-02-07 2008-12-18 The Curators Of The University Of Missouri Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
IL165218A0 (en) * 2002-05-16 2005-12-18 Bayer Cropscience Gmbh Pyridine carboxamide derivatives and their use as pesticides
MXPA05011523A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas.
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
GB0325175D0 (en) 2003-10-28 2003-12-03 Novartis Ag Organic compounds
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
GB0413879D0 (en) 2004-06-21 2004-07-21 Glaxo Group Ltd Compounds
US20060211697A1 (en) 2004-12-08 2006-09-21 Liren Huang 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents
DE102005001411A1 (de) * 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
WO2007103475A2 (en) 2006-03-07 2007-09-13 Beth Israel Deaconess Medical Center, Inc. Transcranial magnetic stimulation (tms) methods and apparatus
SI2656842T1 (sl) 2006-03-27 2016-10-28 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
WO2007127010A2 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
WO2008131276A1 (en) 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
WO2009097998A1 (de) 2008-02-07 2009-08-13 Sanofi-Aventis Arylchalcogeno-arylalkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
EP2242747A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
EP4071169A2 (en) 2008-08-25 2022-10-12 Dana Farber Cancer Institute, Inc. Conserved influenza hemagglutinin epitope and antibodies thereto
CN102256968A (zh) 2008-12-22 2011-11-23 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
WO2010149765A1 (en) 2009-06-26 2010-12-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Non human animal models for increased retinal vascular permeability
JP5788404B2 (ja) 2009-12-11 2015-09-30 アウトイフオンイ トヘラペウトイクス リミテッド イミダゾリジンジオン誘導体
CA2780526A1 (en) 2009-12-14 2011-06-23 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EP2649066B1 (en) * 2010-12-06 2015-10-21 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
US8648070B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
US9193704B2 (en) * 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
US9422252B2 (en) * 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
EP2852588B8 (en) * 2012-05-22 2018-01-10 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors

Similar Documents

Publication Publication Date Title
JP2013513564A5 (https=)
JP6218808B2 (ja) Ｌｒｒｋ２モジュレ−タ−としてのピラゾ−ルアミノピリミジン誘導体
JP5572675B2 (ja) βセクレターゼ阻害作用を有する含硫黄複素環誘導体
US10308659B2 (en) Pyridine derivatives
RU2412937C2 (ru) Соединения трехзамещенного амина и их применение в качестве ингибиторов белка переноса холестерилового эфира (сетр)
RU2634716C2 (ru) Производные аминопиридина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2)
US10787458B2 (en) Chiral synthesis of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-A]pyrazines
CN118812519A (zh) 取代的四氢呋喃作为Nav1.8抑制剂
US10358435B2 (en) Triazolyl pyrimidinone compounds as PDE2 inhibitors
US10160762B2 (en) 6-alkyl dihydropyrazolopyrimidinone compounds as PDE2 inhibitors
ES2976515T3 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad del receptor APJ
US20100087460A1 (en) Arylamide pyrimidone derivatives
US20240083896A1 (en) Nitrogen Containing 2,3-Dihydroquinazolinone Compounds as Nav1.8 Inhibitors
US9815796B2 (en) Pyrimidone carboxamide compounds as PDE2 inhibitors
US10195201B2 (en) Heteroaryl-pyrimidinone compounds as PDE2 inhibitors
US20250304546A1 (en) Compounds for the treatment of a central nervous system disease or disorder
US20250243173A1 (en) Compounds for the treatment of a central nervous system disease or disorder
US20250236602A1 (en) Compounds for the treatment of a central nervous system disease or disorder
US20250388558A1 (en) Compounds for the treatment of a central nervous system disease or disorder
US20250129035A1 (en) Compounds for the treatment of a central nervous system disease or disorder
EP4085054B1 (en) New pqsr inverse agonists
HK40002908B (zh) [1，2，3]三唑并[4，5-d]嘧啶衍生物
HK40002908A (en) Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives